What question did this study set out to answer?

The aim is to evaluate the effectiveness of multimodal ctDNA profiling in detecting minimal residual disease (MRD) in ovarian cancer.

March 1, 2026Open Access

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

Key Points

The aim is to evaluate the effectiveness of multimodal ctDNA profiling in detecting minimal residual disease (MRD) in ovarian cancer.
Conducted the MITO16a/MaNGO-OV2 trial
Utilized ctDNA profiling techniques
Assessed MRD detection and risk stratification in participants
Identified ctDNA as a sensitive method for MRD detection
Enhanced prognostic assessment beyond traditional clinical factors
Supported non-invasive monitoring for therapeutic management

Abstract

Together, these findings establish multimodal ctDNA profiling as a sensitive, non-invasive strategy for MRD detection and longitudinal surveillance in advanced EOC, refining prognostic assessment beyond clinical and surgical factors while paving the way for precision-guided therapeutic management.

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

Key Points

Abstract

Cite This Study

Also Consider

Also Consider